INVESTOR NEWS

Feb 13, 2026

Gentian Diagnostics ASA: Mandatory notification of trade

Moss, 13 February 2026 Gentian Diagnostics ASA ("Gentian") has today been notified that the following..

Feb 12, 2026

Mandatory notification of trade

Moss, 12 February 2026 Gentian Diagnostics ASA ("Gentian") has today been notified that the following..

Feb 12, 2026

Gentian Diagnostics: Key information relating to the proposed cash dividend

Moss, 12 February 2026 The Board of Directors of Gentian Diagnostics ASA proposes a dividend of NOK 0.60 per..

Feb 11, 2026

Update on the development of the NT-proBNP assay

Gentian Diagnostics ASA announces an update on the development of its NT proBNP assay. Recent investigations..

Feb 11, 2026

Gentian Diagnostics: Fourth quarter 2025 report

Moss, 11 February 2026 Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic..

Feb 04, 2026

Gentian Diagnostics: Invitation to presentation of fourth quarter results

Gentian Diagnostics ASA will present its fourth quarter 2025 results on 11 February 2026 at 09.00 CEST.

Jan 07, 2026

Gentian Diagnostics announces exclusive partnership for the development of a novel diagnostic assay with a leading global IVD company

Moss, 7 January 2026 Gentian Diagnostics ASA, a fast-growing developer and manufacturer of high-quality..

Nov 25, 2025

Gentian Diagnostics presents at the DNB Nordic Healthcare Conference

Moss, 25 November 2025 The CEO of Gentian Diagnostics, Mr. Matti Heinonen, will today give a company..